Biotech | February 18, 2022
USFDA clears Kairos Pharma’s IND to treat prostrate cancer
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Funding to grow the insurance and digital therapeutics vertical in India
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
Fast, flexible space allows clinical trials to start when needed. A trial can become operational, pivot or scale without traditional capital building expenditures
In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Subscribe To Our Newsletter & Stay Updated
